CINECA IRIS Institutional Research Information System

MARINO', MICHELE Statistiche

MARINO', MICHELE  

DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE  

Mostra records
Risultati 1 - 20 di 180 (tempo di esecuzione: 0.029 secondi).
Titolo Data di pubblicazione Autore(i) File
In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features 1-gen-2023 Brancatella, A; Torregrossa, L; Viola, N; Sgrò, D; Casula, M; Basolo, F; Materazzi, G; Marinò, M; Marcocci, C; Santini, F; Latrofa, F
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment 1-gen-2022 Gallo, D.; Mortara, L.; Veronesi, G.; Cattaneo, S. A. M.; Genoni, A.; Gallazzi, M.; Peruzzo, C.; Lasalvia, P.; Moretto, P.; Bruno, A.; Passi, A.; Pini, A.; Nauti, A.; Lavizzari, M. A.; Marino, M.; Lanzolla, G.; Tanda, M. L.; Bartalena, L.; Piantanida, E.
Anti-nuclear autoantibodies in Graves' disease and Graves' orbitopathy 1-gen-2022 Lanzolla, G; Puccinelli, L; Giudetti, M; Comi, S; Menconi, F; Maglionico, M N; Posarelli, C; Figus, M; Marcocci, C; Marino, M
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols 1-gen-2022 Dallan, I.; Cristofani-Mencacci, L.; Fiacchini, G.; Benettini, G.; Picariello, M.; Lanzolla, G.; Lazzerini, F.; Rocchi, R.; Turri-Zanoni, M.; Menconi, F.; Sellari-Franceschini, S.; Marino, M.
Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity 1-gen-2022 Bartalena, L.; Marcocci, C.; Tanda, M. L.; Marino, M.
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 1-gen-2022 Rotondo Dottore, G.; Torregrossa, L.; Lanzolla, G.; Mariotti, S.; Menconi, F.; Piaggi, P.; Cristofani Mencacci, L.; Posarelli, C.; Maglionico, M. N.; Dallan, I.; Figus, M.; Nardi, M.; Marcocci, C.; Basolo, F.; Marinò, M.
Sirolimus as a second-line treatment for Graves' orbitopathy 1-gen-2022 Lanzolla, G; Maglionico, M N; Comi, S; Menconi, F; Piaggi, P; Posarelli, C; Figus, M; Marcocci, C; Marino', Michele
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study 1-gen-2022 Douglas, R. S.; Kahaly, G. J.; Ugradar, S.; Elflein, H.; Ponto, K. A.; Fowler, B. T.; Dailey, R.; Harris, G. J.; Schiffman, J.; Tang, R.; Wester, S.; Jain, A. P.; Marcocci, C.; Marino, M.; Antonelli, A.; Eckstein, A.; Fuhrer-Sakel, D.; Salvi, M.; Sile, S.; Francis-Sedlak, M.; Holt, R. J.; Smith, T. J.
Teprotumumab for Graves??? orbitopathy and ototoxicity: moving problems from eyes to ears? 1-gen-2022 Bartalena, L.; Marin??, M.; Marcocci, C.; Tanda, M. L.
Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study 1-gen-2021 Lanzolla, Giulia; Menconi, Francesca; Nicolì, Francesca; Posarelli, Chiara; Maglionico, Maria Novella; Figus, Michele; Nardi, Marco; Marcocci, Claudio; Marinò, Michele
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study 1-gen-2021 Lanzolla, G.; Menconi, F.; Nicoli, F.; Posarelli, C.; Maglionico, M. N.; Figus, M.; Nardi, M.; Marcocci, C.; Marino, M.
Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study 1-gen-2021 Loiudice, Pasquale; Pellegrini, Marco; Marinò, Michele; Mazzi, Barbara; Ionni, Ilaria; Covello, Giuseppe; Figus, Michele; Nardi, Marco; Casini, Giamberto
Genetic profiling of orbital fibroblasts from patients with Graves' orbitopathy 1-gen-2021 Dottore, Giovanna Rotondo; Bucci, Ilaria; Lanzolla, Giulia; Dallan, Iacopo; Sframeli, Angela; Torregrossa, Liborio; Casini, Giamberto; Basolo, Fulvio; Figus, Michele; Nardi, Marco; Marcocci, Claudio; Marinò, Michele
Graves’ disease and Graves’ orbitopathy following COVID-19 1-gen-2021 Lanzolla, G.; Marcocci, C.; Marino, M.
Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease 1-gen-2021 Lanzolla, G.; Marino, M.; Marcocci, C.
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 1-gen-2021 Lanzolla, Giulia; Sabini, Elena; Leo, Marenza; Menconi, Francesca; Rocchi, Roberto; Sframeli, Angela; Piaggi, Paolo; Nardi, Marco; Marcocci, Claudio; Marinò, Michele
Statins: A New Hope on the Horizon of Graves Orbitopathy? 1-gen-2021 Marino, M.; Lanzolla, G.; Marcocci, C.
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy 1-gen-2021 Bartalena, L.; Kahaly, G. J.; Baldeschi, L.; Dayan, C. M.; Eckstein, A.; Marcocci, C.; Marino, M.; Vaidya, B.; Wiersinga, W. M.
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 1-gen-2020 Giani, C.; Ramone, T.; Romei, C.; Ciampi, R.; Tacito, A.; Valerio, L.; Agate, L.; Ugolini, C.; Marino, M.; Basolo, F.; Franchi, A.; Borsari, S.; Michelucci, A.; Selli, C.; Materazzi, G.; Cetani, F.; Elisei, R.
Antioxidant Therapy in Graves’ Orbitopathy 1-gen-2020 Lanzolla, G.; Marcocci, C.; Marino, M.